Cellyan Biotechnology Co., Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HKPD research report →
Price Chart
About the company
Cellyan Biotechnology Co. , Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the international sourcing and distribution of OTC medications, alongside comprehensive e-commerce supply chain management.
- CEO
- Chenyu Liang
- IPO
- 2025
- Employees
- 27
- HQ
- Hong Kong, HK
Get TickerSpark's AI analysis on HKPD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.13M
- P/E
- -4.72
- PEG
- 0.00
- P/S
- 0.08
- P/B
- 0.39
- EV/EBITDA
- -2.36
- Div Yield
- 0.00%
- Gross Margin
- 10.32%
- Op Margin
- -7.41%
- Net Margin
- -8.46%
- ROE
- -15.43%
- ROIC
- -9.18%
Latest fiscal year · YoY change
- Revenue
- $13.43M-33.9%
- Gross Profit
- $1.39M-42.6%
- Op Income
- $-994,902
- Net Income
- $-1,135,963-4098.6%
- EPS
- $-0.05-1688.9%
- OCF Growth
- -232.0%
- FCF Growth
- -290.0%
- 52W High
- $1.72
- 52W Low
- $0.10
- 50D MA
- $0.27
- 200D MA
- $0.53
- Beta
- 2.23
- RSI (14)
- 25
- Avg Volume
- 3.82M
No earnings-call transcripts are available for HKPD yet.
- Free Float
- 29.2%
- Shares Outstanding
- 10.98M
- Float Shares
- 3.21M
of shares held by institutions
4 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Stonex Group Inc. | 102.31K | ▲ 62.91K |
| Jane Street Group, LLC | 49.09K | ▲ 49.09K |
| Hrt Financial LP | 41.82K | ▲ 41.82K |
| Xtx Topco Ltd | 38.93K | ▲ 38.93K |
| Clear Street Group Inc. | 12.02K | 0 |
| Ubs Group AG | 1.08K | ▲ 971 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | CHAN Kam Leung | other | 0 |
| Mar 18, 26 | Wong Lap Sun | other | 0 |
| Mar 18, 26 | Wang Zifeng | other | 0 |
| Mar 18, 26 | Liu Shu | other | 0 |
| Mar 18, 26 | Zhou Mike Yao | other | 0 |
| Mar 18, 26 | Wu Jingyan | other | 0 |
| Mar 18, 26 | Liang Chenyu Andy | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HKPD coverage
Recent articles, reports, and earnings notes.
No research on HKPD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HKPD report →Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
globenewswire.com · Jul 16
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
globenewswire.com · Jan 16
Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders
globenewswire.com · Dec 17
Hong Kong Pharma Digital Technology (NASDAQ:HKPD) Stock Price Up 0.3% – Here’s What Happened
defenseworld.net · Dec 10
DCS Announces Q3 2025 Quarterly Financial Statements
newsfilecorp.com · Dec 1
Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024
prnewswire.com · Mar 28
U.S. IPO Weekly Recap: Oil And Gas Well Equipment Provider Flowco Debuts, While More Sizable Deals Join The Pipeline
seekingalpha.com · Jan 18
Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering
prnewswire.com · Jan 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.